In amyotrophic lateral sclerosis, there is a need for biomarkers to distinguish patients from controls, to follow disease progression and to provide information about the pathogenesis of disease. In a previous mass spectrometry study that searched for potential proteins of interest, we identified clusterin, CD5L, ficolin-3, and gelsolin as molecules that differed in abundance between ALS patients and controls, with a greater difference in patients with cognitive impairment. Here, we have measured levels of these molecules in plasma from a separate cohort of ALS patients and controls. The plasma was depleted of abundant plasma proteins. We confirmed our previous findings that levels of clusterin are decreased and ficolin-3 are increased in ALS patients compared to controls. In this study, we found that levels of CD5L were increased in patients with ALS and levels correlated with survival. We found that levels of gelsolin were modestly increased in ALS compared to controls whereas in our previous study these were decreased, especially in patients with cognitive impairment who were not included in this study. We suggest that clusterin and ficolin-3 deserve further study as potential ALS biomarkers.

在肌萎缩侧索硬化中，需要生物标志物来区分患者与对照组，跟踪疾病进展并提供有关疾病发病机制的信息。在之前的一项寻找潜在目标蛋白质的质谱研究中，我们将凝聚素、CD5L、ficolin-3 和凝溶胶蛋白确定为 ALS 患者和对照组之间丰度不同的分子，认知障碍患者的差异更大。在这里，我们测量了来自不同 ALS 患者和对照组的血浆中这些分子的水平。血浆耗尽了丰富的血浆蛋白。我们证实了我们之前的研究结果，即与对照组相比，ALS 患者的凝聚素水平降低，而 ficolin-3 增加。在这项研究中，我们发现 ALS 患者的 CD5L 水平升高，并且水平与生存相关。我们发现，与对照组相比，ALS 中凝溶胶蛋白的水平略有增加，而在我们之前的研究中，这些水平有所降低，尤其是在未纳入本研究的认知障碍患者中。我们建议，clusterin 和 ficolin-3 作为潜在的 ALS 生物标志物值得进一步研究。